Navigation Links
WorldHeart Announces Delisting Appeal Received and Will be Considered at Hearing July 10, 2008
Date:5/27/2008

OAKLAND, Calif., May 27 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) -- World Heart Corporation (the "Company") today announced that on May 20, 2008, it had received a letter from the NASDAQ Hearings Panel stating that they had received the Company's request to appeal the NASDAQ Listing Qualification Staff determination to delist World Heart Corporation's securities from the NASDAQ Stock Market. Accordingly, the delisting action referenced in the NASDAQ Staff's determination letter has been stayed, pending a final written decision by the NASDAQ Hearings Panel.

This letter provided formal notice that the panel will consider our appeal at an oral/written hearing. The hearing will be held on Thursday, July 10, 2008, at 2:30 PM in Washington, DC.

This decision by the NASDAQ Hearings Panel means that the stock will continue to trade at least until the determination is made at this hearing.

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems. The Company is headquartered in Oakland, California, USA with additional facilities in Salt Lake City, Utah and Herkenbosch, Netherlands. WorldHeart's registered office is Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include any statements regarding the Company's ability to regain compliance with the NASDAQ Capital Market listing requirements, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: the Company's immediate need for additional capital, risks in product development and market acceptance of and demand for the Company's products; delisting from the NASDAQ Stock Market if compliance with the listing standards, including the Minimum Bid Price Rule and other minimum standards, is not regained; and other risks detailed in the Corporation's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-KSB for the year ended December 31, 2007.


'/>"/>
SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
2. WorldHeart 10-KSB Audit Report Includes Going Concern Qualification
3. WorldHeart Schedules Teleconference
4. AMICAS Announces Integrations at More Than 100 MEDITECH Facilities
5. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
6. Epitomics Announces the Creation of 1000th Rabbit Monoclonal Antibody
7. NicOx Announces Departure of Damian Marron for CEO Position
8. CellCyte Genetics Corporation Announces Launch of Comprehensive Web site Powered by PRNewswire Investor Room Backend Technology
9. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
10. Dragon Pharma Announces June 26, 2008 for 2008 Annual Shareholders Meeting
11. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 , ... ... re-engineered Drug Safety Technology Consortium™ (SafeTEC™), $3 million in investment towards 15+ TEC ... new tools and assays, and their applicability in drug safety assessment, for the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... and epigenetics research, recently announced a collaboration with the Heidelberg University Hospital and ... method for library preparation, following the company’s successful launch of its CATS ...
(Date:1/17/2017)... -- On January 10 at the Medtech Showcase held in ... in San Francisco , ProclaRx CEO, ... pharmaceutical leaders and public and private investors about the ... destroy biofilms.  Biofilms are a physical ... body,s immune system from eradicating chronic infections. Infections with biofilms ...
(Date:1/16/2017)... MANHASSET, N.Y. , Jan. 16, 2017   ... Kevin J. Tracey, MD , president and CEO of ... Northwell Health, completed an analysis of how the nervous ... further identify and develop bioelectronic medicine devices ... today in Nature Neuroscience . The ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 "Increase in mobile transactions is driving ... biometrics market is expected to grow from USD 4.03 ... at a CAGR of 29.3% between 2016 and 2022. ... growing demand for smart devices, government initiatives, and increasing ... component is expected to grow at a high rate ...
(Date:12/7/2016)... BioCatch , the global leader in behavioral biometrics, reported a ... over 40 granted and pending patents. ... , The Company,s IP portfolio expansion ... Device, and Method Estimating Force Applied to a Touch Surface, " ... components needed to estimate the force and pressure applied to touch surfaces ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):